Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025 [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The companies that make those drugs predict. The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S's (NYSE: NVO ) Wegvoy (semaglutide) in 2021. Eli Lilly And Co's (NYSE: LLY ) Zepbound (tirzepatide) appears to spur the momentum after receiving FDA approval in November 2023. According to the FDA, limited supplies of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound are expected through the second quarter of this year due to heightened demand NBC's Christine Romans reports for TODAY on how companies are trying to keep up with demand. TODAY's report notes that America's relationship with weight loss is dramatically transforming as drugs from Eli and Novo Nordisk are changing the game. Related: Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy Sales surged to almost $11 billion in 2023 from $4 billion in 2022, and demand is outpacing supply. In the North Carolina site, t
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- UK's FTSE 100 Edges Lower in Thin Trading Ahead of Fed Decision [BNN Bloomberg (Canada)]BNN Bloomberg
- Denmark, home of Ozempic, feels the drug's effects [Yahoo! Finance]Yahoo! Finance
- Amgen Q1 Earnings Preview: Obesity treatment updates to be the focus this season [Seeking Alpha]Seeking Alpha
- Amgen investors await weight-loss drug data [Yahoo! Finance]Yahoo! Finance
- Amgen investors await weight-loss drug data [Reuters]Reuters
NVO
Earnings
- 11/3/23 - Beat
NVO
Sec Filings
- 5/1/24 - Form 6-K
- 4/26/24 - Form 6-K
- 4/25/24 - Form 6-K
- NVO's page on the SEC website